We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Iron Levels in Brain May Predict MS Disabilities

By MedImaging International staff writers
Posted on 10 Sep 2018
Print article
Image: A highly accurate MRI technique can monitor iron levels in the brains of MS patients (Photo courtesy of RSNA).
Image: A highly accurate MRI technique can monitor iron levels in the brains of MS patients (Photo courtesy of RSNA).
A new study describes a highly accurate magnetic resonance imaging (MRI) technique that suggests altered deep gray matter iron is associated with the evolution of multiple sclerosis (MS).

Researchers at the University at Buffalo (UB; NY, USA) and the Buffalo Neuroimaging Analysis Center (BNAC; NY, USA) conducted a prospective study in 600 participants with MS to examine deep gray matter using quantitative susceptibility mapping (QSM), and to assess the relationship between susceptibility and clinical disability. All MS patients, and 250 age- and sex-matched healthy control participants were imaged with a 3T MRI scanner to measure deep gray matter magnetic susceptibility, using region of interest and voxelwise methods.

The results revealed that the MS patients had higher levels of iron in the basal ganglia than the control patients. On the other hand, MS patients had lower levels of iron in the thalamus, an important brain region that helps process sensory input by acting as a relay between certain brain structures and the spinal cord. Lower iron content in the thalamus and higher iron content in other deep gray matter structures in MS patients were associated with longer disease duration, higher disability degree, and faster disease progression. The study was published on July 17, 2018, in Radiology.

“Brain atrophy is the current gold standard for predicting cognitive and physical decline in MS, but it has limitations; it takes a long time to see. We need an earlier measure of who will develop MS-related disability,” said lead author Professor Robert Zivadinov, MD, PhD, of UB and BNAC. “The results point to a potential role for quantitative susceptibility mapping in clinical trials of promising new drugs. To be able to act against changes in susceptibility would be extremely beneficial.”

The role of iron accumulation in white and gray matter damage in MS is well known, but it is not yet clear if local changes in brain tissue iron concentrations are a causal factor in neurodegeneration, or a by-product of cell death. Histopathologic and MRI data have consistently shown profound changes in iron concentration in all the central nervous system compartments, with reduced iron content in newly forming white matter lesions, cortical lesions, thalamus and normal-appearing white matter, and higher iron content in the rim of chronic active lesions and structures of the basal ganglia.

Related Links:
University at Buffalo
Buffalo Neuroimaging Analysis Center

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound System
Acclarix AX9
New
Ultrasound System
P20 Elite
New
Pre-Op Planning Solution
Sectra 3D Trauma

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.